InvestorsHub Logo
icon url

SF Anony

03/30/21 9:44 AM

#155540 RE: B52T38 #155536

I’m not a Doctor or a Smart, but I think that the known safety profile is what allowed Cytodyn to go straight to a Phase II trail last Spring.
icon url

Rockleo

03/30/21 10:53 AM

#155569 RE: B52T38 #155536

B52T38.. From what I gather..The FDA threatened to delay the start of our trial by 6 months..if we insisted on first dose IV..Weekly dose for Day 0..7..14..21..CYDY was forced to do 2 doses ONLY..So as to expose LERONLIMAB to the World..!!!
icon url

Bill_ENG

03/30/21 11:07 AM

#155581 RE: B52T38 #155536

My hope is that nations like Hungary who actually ask for the data can be open minded enough to see the benefit of using LL and buy up the supply.

The US can get to back of the line. They had a chance at this for a year and spurned it, let it go where it will be used.




icon url

misiu143

03/30/21 11:38 AM

#155601 RE: B52T38 #155536

B52T38 , after what happened with Remdesivir study , changing primary endpoint at the end of the study, and then approving within 2-3 days , with uch a poor results ...
and many safe , much better drugs going thru delays ,

I don't know how to answer your question , maybe others will..

GLTU.

IMO.